• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>The Primary Care Companion for CNS Disorders >Effect of Bupropion SR on the Quality of Life of Elderly Depressed Patients With Comorbid Medical Disorders
【2h】

Effect of Bupropion SR on the Quality of Life of Elderly Depressed Patients With Comorbid Medical Disorders

机译：安非他酮对老年抑郁症合并疾病患者的生活质量的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

>Background: There is a need for additional studies of the quality of life (QOL) of elderly depressed subjects with medical comorbidity.>Method: We conducted an 8-week, open trial of bupropion sustained release (SR) in 18 elderly (60–81 years) subjects with DSM-IV major depressive disorder and one or more serious medical illnesses (e.g., congestive heart failure, type 1 diabetes mellitus, irritable bowel syndrome) with a week-12 follow-up interview. The intent-to-treat method with the last observation carried forward was used to analyze depression and QOL measures. Dosing was initiated at 100 mg once daily and increased at weekly intervals to a maximum of 150 mg twice daily as clinically indicated.>Results: Bupropion SR treatment was associated with reductions in Clinical Global Impressions-Severity of Illness scale (p < .0001) score and in the 17-item Hamilton Rating Scale for Depression (HAM-D) total score (p < .0001). QOL as measured by the Medical Outcomes Study Short Form-36 (SF-36) also tended to improve with treatment. The SF-36 “mental health” (p < .01) and “social functioning” (p < .0006) domains improved significantly by week 4. “Vitality” (p < .03) improved significantly by week 12. On the HAM-D, statistically significant improvement was noted on “depressed mood” (p < .0001), “feelings of guilt” (p < .01), “work and activities” (p < .001), “hypochondriasis” (p < .02), and “insomnia” (p < .01) at week 8. The mean dose of bupropion SR at endpoint was 222 mg/day, and the drug was relatively well tolerated. Two subjects dropped out owing to adverse events and 2 owing to other reasons. No drug-drug interactions occurred.>Conclusion: These data suggest that bupropion SR is well tolerated and may improve depression, insomnia, somatic symptoms, work functioning, and certain quality-of-life measures in elderly depressed subjects with medical disorders. A randomized, placebo-controlled study is warranted to confirm these promising findings.
机译：>背景：需要对患有合并症的老年抑郁症患者的生活质量（QOL）进行其他研究。>方法：我们进行了为期8周的开放式试验DSM-IV重度抑郁症和一种或多种严重内科疾病（例如充血性心力衰竭，1型糖尿病，肠易激综合征）的18名老年人（60-81岁）的安非他酮缓释（SR） -12个后续采访。最后进行观察的意向性治疗方法用于分析抑郁症和QOL措施。开始剂量为每天一次100 mg，临床指示为每周两次，每次最多增加150 mg。>结果：安非他酮SR治疗可降低临床总体印象-疾病严重程度（p <.0001）得分和汉密尔顿抑郁量表（HAM-D）总得分（p <.0001）。根据医学结果研究简短表格36（SF-36）测得的生活质量也随治疗而改善。到第4周，SF-36的“精神健康”（p <.01）和“社交功能”（p <.0006）域显着改善。“生命力”（p <.03）在第12周时显着改善。 -D在“情绪低落”（p <.0001），“内感”（p <.01），“工作和活动”（p <.001），“软骨病”（p < .02）和第8周时出现“失眠”（p <.01）。终点时安非他酮SR的平均剂量为222 mg / day，并且药物的耐受性相对较好。两名受试者由于不良事件而辍学，而两名则由于其他原因而退学。没有发生药物相互作用。>结论：这些数据表明安非他酮SR具有良好的耐受性，可以改善老年抑郁症患者的抑郁，失眠，躯体症状，工作功能和某些生活质量指标患有医学疾病。有必要进行一项随机，安慰剂对照的研究，以证实这些有希望的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号